Debrisoquine
Names | |
---|---|
Preferred IUPAC name 3,4-Dihydroisoquinoline-2(1H)-carboximidamide | |
Identifiers | |
CAS Number |
|
3D model (JSmol) |
|
ChEBI |
|
ChEMBL |
|
ChemSpider |
|
DrugBank |
|
ECHA InfoCard | 100.013.155 |
KEGG |
|
MeSH | Debrisoquine |
PubChem CID |
|
UNII |
|
CompTox Dashboard (EPA) |
|
InChI
| |
| |
Properties | |
Chemical formula | C10H13N3 |
Molar mass | 175.23032 |
Pharmacology | |
C02CC04 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Y verify (what is YN ?) Infobox references |
Chemical compound
Debrisoquine is a derivative of guanidine. It is an antihypertensive drug similar to guanethidine. Debrisoquine is frequently used for phenotyping the CYP2D6 enzyme, a drug-metabolizing enzyme.[2]
See also
The guanidine part of the molecule also appears in guanoxan and guanadrel.
- The 7-bromo analog of Debrisoquine is called Guanisoquin.
References
- ^ Debrisoquine – Compound Summary, PubChem.
- ^ Fuhr, U.; Jetter, A.; Kirchheiner, J. (2007). "Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the "Cocktail" Approach". Clinical Pharmacology & Therapeutics. 81 (2): 270–283. doi:10.1038/sj.clpt.6100050.
- v
- t
- e
(antagonize α-adrenergic
vasoconstriction)
Central |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Peripheral |
|
Serotonin receptor antagonists | |
---|---|
Endothelin receptor antagonists (for PHTooltip Pulmonary hypertension) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e